Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044083 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Tolcapone for Cognition in Schizophrenia
A Phase 2 study, sponsored by National Institute of Mental Health (NIMH).
- Terminated
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT00044083 is a Phase 2 study that was terminated before completion, run by National Institute of Mental Health (NIMH). The registered enrollment target is 210 participants.
The verdict
NCT00044083, a Phase 2 study, was terminated before completion, sponsored by National Institute of Mental Health (NIMH).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. ...
Interventions
- OTHER Placebo
- DRUG Tolcapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2002-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044083
The ClinicalTrials.gov registry entry for NCT00044083 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00044083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044083 about?
NCT00044083 is a clinical study titled "Clinical Trial of Tolcapone for Cognition in Schizophrenia". This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the br...
What is the current status of trial NCT00044083?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2002-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00044083?
The interventions under investigation include: Placebo (OTHER), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT00044083?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.